We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-1.7%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
-$132M
(-4.3%)
Cap. Flow
-$33.9M
Cap. Flow
% of AUM
-1.15%
Top 10 Holdings %
Top 10 Hldgs %
52.45%
Holding
59
New
22
Increased
10
Reduced
13
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$169M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$104M |
| 3 |
Zimmer Biomet
ZBH
|
+$95.7M |
| 4 |
Agilent Technologies
A
|
+$73.9M |
| 5 |
UnitedHealth
UNH
|
+$69.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$202M |
| 2 |
Medtronic
MDT
|
+$151M |
| 3 |
Incyte
INCY
|
+$110M |
| 4 |
CELG
Celgene Corp
CELG
|
+$100M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Bristol-Myers Squibb
BMY
$134B
| $38M | 1.29% |
601,080
+196,410
| +49% | +$12.6M |
|
27
CALL
AbbVie
ABBV
$433B
| $37.9M | 1.29% |
+400,000
| New | +$43.9M |
|
28
Cencora
COR
$60B
| $36.6M | 1.24% |
+424,230
| New | +$40.8M |
|
29
Haemonetics
HAE
$3.94B
| $36.4M | 1.24% |
497,410
-952,590
| -66% | -$65.4M |
|
|
MDCO
30
DELISTED
Medicines Co
MDCO
| $32.5M | 1.1% |
+985,222
| New | +$30.8M |
|
|
EVHC
31
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $31.3M | 1.07% |
+814,840
| New | +$30.5M |
|
32
Acadia Pharmaceuticals
ACAD
$4.39B
| $31M | 1.05% |
+1,378,000
| New | +$38.2M |
|
|
AVNS
33
DELISTED
Avanos Medical
AVNS
| $28.9M | 0.98% |
+627,500
| New | +$29.8M |
|
|
CVRS
34
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $27.4M | 0.93% |
19,981,655
| – | – |
|
|
CELG
35
CALL
DELISTED
Celgene Corp
CELG
| $26.8M | 0.91% |
+300,000
| New | +$28.8M |
|
|
DVAX
36
DELISTED
Dynavax Technologies
DVAX
| $26.2M | 0.89% |
+1,318,612
| New | +$22.8M |
|
37
Bio-Rad Laboratories Class A
BIO
$8.96B
| $25.7M | 0.88% |
+102,940
| New | +$26.2M |
|
|
38
Vertex Pharmaceuticals
VRTX
$119B
| $24.4M | 0.83% |
149,790
-575,210
| -79% | -$94M |
|
39
Puma Biotechnology
PBYI
$391M
| $19.9M | 0.68% |
+293,130
| New | +$21.9M |
|
40
Mettler-Toledo International
MTD
$29.2B
| $19.3M | 0.66% |
+33,649
| New | +$21.2M |
|
|
XENT
41
DELISTED
Intersect ENT, Inc
XENT
| $18.3M | 0.62% |
+464,850
| New | +$17M |
|
|
ACOR
42
DELISTED
Acorda Therapeutics
ACOR
| $18.2M | 0.62% |
+6,413
| New | +$19.2M |
|
43
Boston Scientific
BSX
$72B
| $15.7M | 0.53% |
573,480
+205,648
| +56% | +$5.59M |
|
|
44
Incyte
INCY
$24B
| $10.9M | 0.37% |
130,910
-1,219,090
| -90% | -$110M |
|
|
45
Medtronic
MDT
$111B
| $9.56M | 0.33% |
119,120
-1,830,880
| -94% | -$151M |
|
|
ZSAN
46
DELISTED
Zosano Pharma Corporation
ZSAN
| $2.77M | 0.09% |
+15,714
| New | +$5.26M |
|
47
Abbott
ABT
$185B
| – | – |
-244,950
| Closed | -$14M |
|
48
CVS Health
CVS
$134B
| – | – |
-1,125,000
| Closed | -$81.6M |
|
49
Humana
HUM
$45B
| – | – |
-263,440
| Closed | -$65.4M |
|
50
Johnson & Johnson
JNJ
$613B
| – | – |
-194,610
| Closed | -$27.2M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2018 Portfolio in Review
As of Q1 2018, HealthCor Management held 59 positions worth $2.94B, down 4.3% from $3.07B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
HealthCor Management's Q1 2018 filing shows 22 new, 10 increased, 13 reduced and 13 closed positions. Its largest new stake was Dentsply Sirona: 2,875,000 shares worth $145M. The largest sale was Bioverativ Inc. Common Stock, an estimated $202M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 100% a quarter earlier.
- HealthCor Management's largest Q1 2018 buy was Dentsply Sirona: 2,875,000 shares worth $145M.
- HealthCor Management added most to Regeneron Pharmaceuticals in Q1 2018, an estimated $104M increase.
- HealthCor Management's biggest Q1 2018 reduction was Medtronic, cutting an estimated $151M.
- HealthCor Management fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $202M.
- HealthCor Management's ten largest holdings make up 52% of its $2.94B portfolio in Q1 2018.
- HealthCor Management opened 22 new positions and closed 13 in Q1 2018.
- HealthCor Management's portfolio value fell 4.3% quarter-over-quarter to $2.94B.
Based on HealthCor Management's 13F filing for Q1 2018, filed 15 May 2018.